Skip to main content

Advertisement

SpringerLink
Log in

The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

PG11047 is a polyamine analog currently in Phase I trials for advanced cancer as a monotherapy and in combination with a number of approved anti-cancer agents. The use of polyamines as a target for antiproliferative therapy is based on findings that cells synthesize polyamines excessively when induced to grow and that polyamine metabolism is frequently dysregulated in cancer. A selective polyamine transport system provides access for PG11047 into rapidly dividing cells to inhibit polyamine biosynthetic enzymes, to induce the polyamine catabolic enzymes spermidine/spermine N 1-acetyltransferase (SSAT) and spermine oxidase (SMO) which could subsequently induce reactive oxygen species that contribute to tumor cell responses to PG11047, and to function as a polyamine with altered function when it binds to natural polyamine binding sites. The objective of the present study was to assess the antitumor effects of PG11047 alone and in combination with approved anti-cancer agents.

Methods

The antitumor efficacy of PG11047 as a single agent, and in combination with cisplatin and bevacizumab, was tested in models of lung (A549) and prostate (DU-145) cancer, respectively.

Results

PG11047 significantly inhibited tumor development in both lung and prostate cancer models when administered as a single agent. In the lung cancer model, PG11047 potentiated the antitumor effect of cisplatin. Although potent activity was observed with PG11047 and bevacizumab when administered as single agents in the prostate cancer model, the combination arm significantly enhanced antitumor activity compared with either agent alone. In all experiments, PG11047 was well tolerated with no adverse effects on bodyweight gain.

Conclusions

The preclinical data support the rationale for the current Phase I trials which are assessing PG11047 as a monotherapy and in combination with a number of approved anti-cancer agents including cisplatin and bevacizumab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Heby O (1981) Role of polyamines in the control of cell proliferation and differentiation. Differentiation 19:1–20

    Article  PubMed  CAS  Google Scholar 

  2. Janne J, Alhonen L, Leinonen P (1991) Polyamines: from molecular biology to clinical applications. Ann Med 23:241–259

    Article  PubMed  CAS  Google Scholar 

  3. Tabor CW, Tabor H (1984) Polyamines. Annu Rev Biochem 53:749–790

    Article  PubMed  CAS  Google Scholar 

  4. Igarashi K, Kashiwagi K (2000) Polyamines: mysterious modulators of cellular functions. Biochem Biophys Res Commun 271:559–564

    Article  PubMed  CAS  Google Scholar 

  5. Matsufuji S, Matsufuji T, Miyazaki Y et al (1995) Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell 80:51–60

    Article  PubMed  CAS  Google Scholar 

  6. Casero RA Jr, Marton LJ (2007) Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 6:373–390

    Article  PubMed  CAS  Google Scholar 

  7. Seiler N (2005) Pharmacological aspects of cytotoxic polyamine analogs and derivatives for cancer therapy. Pharmacol Ther 107:99–119

    Article  PubMed  CAS  Google Scholar 

  8. Reddy VK, Valasinas A, Sarkar A et al (1998) Conformationally restricted analogues of 1N, 12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines. J Med Chem 41:4723–4732

    Article  PubMed  CAS  Google Scholar 

  9. Valasinas A, Sarkar A, Reddy VK et al (2001) Conformationally restricted analogues of 1N, 14N-bisethylhomospermine (BE-4–4-4): synthesis and growth inhibitory effects on human prostate cancer cells. J Med Chem 44:390–403

    Article  PubMed  CAS  Google Scholar 

  10. Huang Y, Pledgie A, Casero RA et al (2005) Molecular mechanisms of polyamine analogs in cancer cells. Anticancer Drugs 16:229–241

    Article  PubMed  CAS  Google Scholar 

  11. Holst CM, Frydman B, Marton LJ, Oredsson SM (2006) Differential polyamine analogue effects in four human breast cancer cell lines. Toxicology 223:71–81

    Article  PubMed  CAS  Google Scholar 

  12. Hacker A, Marton LJ, Sobolewski M, Casero RA Jr (2008) In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells. Cancer Chemother Pharmacol 63(1):45–53

    Article  PubMed  CAS  Google Scholar 

  13. Mitchell JL, Thane TK, Sequeira JM et al (2007) Antizyme and antizyme inhibitor activities influence cellular responses to polyamine analogs. Amino Acids 33:291–297

    Article  PubMed  CAS  Google Scholar 

  14. Ha HC, Woster PM, Yager JD et al (1997) The role of polyamine catabolism in polyamine analogue-induced programmed cell death. Proc Natl Acad Sci USA 94:11557–11662

    Article  PubMed  CAS  Google Scholar 

  15. Wang Y, Devereux W, Woster PM (2001) Cloning and characterization of a human polyamine oxidase that is inducible by polyamine analogue exposure. Cancer Res 61:5370–5373

    PubMed  CAS  Google Scholar 

  16. Wang Y, Murray-Stewart T, Devereux W (2003) Properties of purified recombinant human polyamine oxidase PAOh/SMO. Biochem Biophys Res Commun 304:605–611

    Article  PubMed  CAS  Google Scholar 

  17. Devereux W, Wang Y, Stewart TM (2003) Induction of the PAOh1/SMO polyamine oxidase by polyamine analogues in human lung carcinoma cells. Cancer Chemother Pharmacol 52(5):383–390

    Article  PubMed  CAS  Google Scholar 

  18. Hawthorn TR, Austin JK Jr (1996) Synergism of the polyamine analogue, N1, N11-bisethylnorspermine with cis-diaminedichloroplatinum (II) against murine neoplastic cell lines in vitro and in vivo. Cancer Lett 99(1):99–107

    Article  Google Scholar 

  19. Svensson KJ, Welch JE, Kucharzewska P (2008) Hypoxia-mediated induction of the polyamine system provides opportunities for tumor growth inhibition by combined targeting of vascular endothelial growth factor and ornithine decarboxylase. Cancer Res 68(22):9291–9301

    Article  PubMed  CAS  Google Scholar 

  20. Wallace HM, Fraser AV, Hughes A (2003) A perspective of polyamine metabolism. Biochem J 376:1–14

    Article  PubMed  CAS  Google Scholar 

  21. Liang WC, Wu X, Peale FV et al (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281(2):951–961

    Article  PubMed  CAS  Google Scholar 

  22. Allen WL, McLean EG, Boyer J et al (2007) The role of spemidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells. Mol Cancer Ther 6(1):128–137

    Article  PubMed  CAS  Google Scholar 

  23. Varma R, Hector S, Greco WR et al (2007) Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Cancer Chemother Pharmacol 59:711–723

    Article  PubMed  CAS  Google Scholar 

  24. Morrison RF, Seidel ER (1995) Vascular endothelial cell proliferation: regulation of cellular polyamines. Cardiovasc Res 29:841–847

    PubMed  CAS  Google Scholar 

  25. Carew JS, Nawrocki ST, Reddy VK et al (2008) The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. Cancer Res 68:4783–4790

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Progen Pharmaceuticals Ltd, PO Box 2403, Toowong, Brisbane, QLD, 4066, Australia

    K. Dredge & I. Bytheway

  2. Quintessence Biosciences, Madison, WI, USA

    J. A. Kink

  3. KAI Pharmaceuticals, South San Francisco, CA, 94080, USA

    R. M. Johnson

  4. Progen Pharmaceuticals Inc, Redwood City, CA, USA

    L. J. Marton

Authors
  1. K. Dredge
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. A. Kink
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. M. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Bytheway
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. J. Marton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Dredge.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dredge, K., Kink, J.A., Johnson, R.M. et al. The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer. Cancer Chemother Pharmacol 65, 191–195 (2009). https://doi.org/10.1007/s00280-009-1105-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-009-1105-7

Keywords

Search

Navigation